|
|
|
|
| LEADER |
01325nam a2200253 u 4500 |
| 001 |
EB002136309 |
| 003 |
EBX01000000000000001274436 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
221206 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Satralizumab (Enspryng)
|h Elektronische Ressource
|b (Hoffmann-La Roche Limited) : indication neuromyelitis optica spectrum disorder
|
| 246 |
3 |
1 |
|a Satralizumab (Enspryng)
|
| 246 |
3 |
1 |
|a Clinical review report for satralizumab (Enspryng)
|
| 250 |
|
|
|a Version: Final (with redactions)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2021, June 2021
|
| 300 |
|
|
|a 1 PDF file (92 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK583306
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a The objective of this report is to perform a systematic review of the beneficial and harmful effects of satralizumab as monotherapy or in combination with immunosuppressive therapy for the treatment of NMOSD in adult and adolescent patients who are AQP4 antibody positive
|